8-KMaterial AgreementsExhibits & Filings

ELI LILLY & Co 8-K Report, Material Agreement (Oct 10, 2008)

Filed October 10, 2008For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on October 9, 2008, reporting on a material definitive agreement entered into on October 5, 2008. While the filing itself is sparse on details within the provided text, the designation of 'Item 1.01 Entry into a Material Definitive Agreement' signifies a significant business development for the company. Investors should be aware that such agreements often involve collaborations, acquisitions, licensing deals, or significant partnerships that could impact future revenue streams, product pipelines, or market positioning. Further investigation into the full SEC filing, specifically the attached exhibits and any related press releases, is crucial for understanding the specific nature and implications of this agreement. The absence of detailed financial statements in the provided snippet (Item 9.01) suggests that the primary focus of this particular filing is the announcement of the agreement itself, rather than immediate financial reporting related to it. Investors should look for information regarding the counterparty, the scope of the agreement, and any potential financial commitments or benefits.

Key Highlights

  • 1Eli Lilly & Co. (LLY) filed an 8-K on October 9, 2008.
  • 2The filing pertains to a material definitive agreement entered into on October 5, 2008.
  • 3Item 1.01 indicates a significant business development for the company.
  • 4This type of agreement could involve collaborations, acquisitions, licensing, or strategic partnerships.
  • 5The filing suggests a potential impact on Lilly's future financial performance and strategic direction.
  • 6Investors need to review the full filing, including exhibits, for specific details.
  • 7The provided text does not include immediate financial reporting related to the agreement.

Frequently Asked Questions

The provided text of the 8-K filing indicates that Eli Lilly entered into a material definitive agreement on October 5, 2008. However, the specific details of the agreement (e.g., acquisition, partnership, licensing) are not detailed in the excerpt. Investors would need to consult the full SEC filing, particularly any attached exhibits or related press releases referenced in the filing, for comprehensive information.

Material definitive agreements are significant because they often represent strategic moves by a company that can materially affect its business, operations, or financial condition. This could involve expanding market reach, acquiring new technologies, entering new therapeutic areas, or forming key alliances, all of which can impact future revenue, profitability, and shareholder value.

To find more details about this material definitive agreement, investors should access the complete Eli Lilly & Co. 8-K filing for October 9, 2008, through the SEC's EDGAR database or a reputable financial data provider. Look specifically for the exhibits filed along with the 8-K, as these typically contain the actual agreement or a summary thereof, and any associated press releases.